CervoMed Inc. (CRVO) - Total Assets
Based on the latest financial reports, CervoMed Inc. (CRVO) holds total assets worth $30.61 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CervoMed Inc. book value and equity for net asset value and shareholders' equity analysis.
CervoMed Inc. - Total Assets Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s total assets have evolved over time, based on quarterly financial data.
CervoMed Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
CervoMed Inc.'s total assets of $30.61 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.9% |
| Accounts Receivable | $2.25 Million | 5.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of CervoMed Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: CervoMed Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 93.0% in 1998.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2024, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
CervoMed Inc. Competitors by Total Assets
Key competitors of CervoMed Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CervoMed Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.66 | 15.04 | 7.71 |
| Quick Ratio | 6.66 | 15.04 | 7.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $26.01 Million | $45.56 Million | $16.34 Million |
CervoMed Inc. - Advanced Valuation Insights
This section examines the relationship between CervoMed Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | 332.0% |
| Total Assets | $43.08 Million |
| Market Capitalization | $34.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values CervoMed Inc.'s assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CervoMed Inc.'s assets grew by 332.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CervoMed Inc. (1998–2024)
The table below shows the annual total assets of CervoMed Inc. from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.08 Million | +332.00% |
| 2023-12-31 | $9.97 Million | +139.86% |
| 2022-12-31 | $4.16 Million | -89.01% |
| 2021-12-31 | $37.84 Million | +36.46% |
| 2020-12-31 | $27.73 Million | +14.21% |
| 2019-12-31 | $24.28 Million | +33.38% |
| 2018-12-31 | $18.20 Million | -30.38% |
| 2017-12-31 | $26.15 Million | +49.54% |
| 2016-12-31 | $17.48 Million | +668.01% |
| 2015-12-31 | $2.28 Million | -94.68% |
| 2014-12-31 | $42.78 Million | +133.20% |
| 2013-12-31 | $18.34 Million | +649.87% |
| 2012-12-31 | $2.45 Million | -33.41% |
| 2011-12-31 | $3.67 Million | -34.11% |
| 2010-12-31 | $5.58 Million | +30.18% |
| 2009-12-31 | $4.28 Million | -20.13% |
| 2008-12-31 | $5.36 Million | -20.00% |
| 2007-12-31 | $6.70 Million | -69.78% |
| 1999-12-31 | $22.18 Million | +19.90% |
| 1998-12-31 | $18.50 Million | -- |
About CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more